Case Reports - Successful Treatment with Nab-paclitaxel after Hypersensitivity Reaction to Paclitaxel and Docetaxel

open access

Highlights

•

First case report of successfully treating severe paclitaxel and docetaxel hypersensivity reaction with nab-paclitaxel.

•

We demonstrated that nab-paclitaxel is a safe taxane chemotherapy treatment option for patients who could not tolerate paclitaxel or docetaxel.

---

Introduction

The standard treatment for patients with ovarian cancer is the combination of platinum and taxane chemotherapy.. However, one of the limitations in using paclitaxel and docetaxel is the hypersensitivity reaction (HSR) that patients’ experience. Despite pretreatment during initial infusion severe HSR could occur in 2% of the cases. For patients who develop HSR to paclitaxel there is the danger of cross reactivity with docetaxel and has been reported to be as high as 90% as previously published by Dizon et al. [1].

The etiology of HSR to paclitaxel and docetaxel is poorly understood. It is believed that the solvent Cremophor EL in paclitaxel, and polysorbate80 in docetaxel may be the cause of HSR. Yet, others have demonstrated that HSR maybe secondary to the direct effect of the taxane itself [2] and not the diluents. There have been several reports that nab-paclitaxel can be safely administered after HSR to paclitaxel [3] but no reported cases of safely administering nab-paclitaxel after HSR to both paclitaxel and docetaxel.

Case Report:

This is a 60 year old female who presented with abdominal pain and bloating. A CT scan of abdomen and pelvis in 7/2012 showed ascites, 16 cm complex pelvic mass and omental caking. In 9/2012 she was brought to the operating room for tumor debulking, however intraoperatively she became hypotensive and unstable. Only partial omentectomy could be performed and pathology was consistent with serous carcinoma from ovarian primary.

In 9/2012 she received her first cycle of neoadjuvant carboplatin and paclitaxel. She was premedicated (diphenhydramine 50 mg IV, decadron 20 mg IV and famotidine 20 mg IV) prior to starting paclitaxel (175 mg/m²/3 hrs) however, twenty minutes into the infusion she developed urticarial rash and went to respiratory distress with O2 saturation of 60% on room air. Infusion was discontinued and she received epinephrine and solumedrol with resolution of symptoms and improvement of vital signs. In 10/2012, she received second cycle of carboplatin (5 AUC) without complications and received docetaxel (75 mg/m²/1 hr) as a replacement for paclitaxel. Despite receiving premedication with decadron 20 mg IV and diphenhydramine 25 mg IV, ten minutes into the docetaxel infusion she developed dyspnea and hypoxia. Given second episode of HSR with taxane, we administered liposomal doxorubicin on her third cycle of chemotherapy; but unfortunately she also developed HSR to liposomal doxorubicin. Given her history of HSR to paclitaxel, docetaxel and liposomal doxorubicin, a decision was made to try nab-paclitaxel. In 11/2012 she received her first cycle of nab-paclitaxel (100 mg/m²/30 mins) in an outpatient setting after receiving dexamethasone 20 mg IV and diphenhydramine 50 mg IV without evidence of HSR. She subsequently received two more cycles without complications. After six cycles of carboplatin and three cycles of nab-paclitaxel, a repeat CT showed good tumor response and she had an uncomplicated optimal, interval tumor debulking..........

"....Nab-paclitaxel may not be the treatment of choice after HSR to paclitaxel as little is known about its effectiveness in ovarian cancer. Nab-paclitaxel is a solvent free, albumin bound paclitaxel that is administered without requiring premedication. Although there are no studies that show equivalent effectiveness of nab-paclitaxel to paclitaxel or docetaxel, there is a phase II GOG trial [5] that has demonstrated that nab-paclitaxel may be effective in patients’ who have recurrent or persistent platinum resistant ovarian cancer."